Sanofi (SNY) Stake Lowered by HM Payson & Co.
HM Payson & Co. cut its stake in Sanofi (NYSE:SNY) by 4.2% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 53,238 shares of the company’s stock after selling 2,338 shares during the period. HM Payson & Co.’s holdings in Sanofi were worth $2,551,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently made changes to their positions in SNY. Conning Inc. bought a new stake in Sanofi during the first quarter worth about $242,000. Hamlin Capital Management LLC raised its stake in Sanofi by 11.8% in the first quarter. Hamlin Capital Management LLC now owns 1,768,523 shares of the company’s stock worth $80,026,000 after buying an additional 186,280 shares during the period. Russell Investments Group Ltd. raised its stake in Sanofi by 1,298.6% in the first quarter. Russell Investments Group Ltd. now owns 565,750 shares of the company’s stock worth $25,596,000 after buying an additional 525,300 shares during the period. Mondrian Investment Partners LTD raised its stake in Sanofi by 32.0% in the first quarter. Mondrian Investment Partners LTD now owns 1,250,842 shares of the company’s stock worth $56,601,000 after buying an additional 302,995 shares during the period. Finally, First Mercantile Trust Co. bought a new stake in Sanofi during the first quarter worth about $339,000. Institutional investors own 9.90% of the company’s stock.
Sanofi (NYSE:SNY) opened at 48.19 on Friday. The company has a market cap of $121.03 billion, a price-to-earnings ratio of 11.43 and a beta of 0.88. The company’s 50-day moving average is $47.84 and its 200 day moving average is $46.41. Sanofi has a 12 month low of $36.81 and a 12 month high of $50.24.
Sanofi (NYSE:SNY) last released its earnings results on Monday, July 31st. The company reported $0.74 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.74. The firm had revenue of $8.66 billion for the quarter, compared to analysts’ expectations of $8.71 billion. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. The company’s revenue was down 2.3% compared to the same quarter last year. Equities analysts forecast that Sanofi will post $3.26 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This article was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/08/20/sanofi-sny-stake-lowered-by-hm-payson-co.html.
A number of research firms have recently issued reports on SNY. Argus increased their price target on shares of Sanofi from $50.00 to $55.00 and gave the stock a “buy” rating in a research report on Friday, June 9th. Cowen and Company reissued a “market perform” rating and issued a $52.00 price target (up from $46.00) on shares of Sanofi in a research report on Tuesday, August 1st. TheStreet raised shares of Sanofi from a “c+” rating to a “b-” rating in a research report on Monday, April 24th. BidaskClub raised shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Saturday, August 5th. Finally, Zacks Investment Research lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Tuesday, April 25th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have issued a buy rating to the stock. Sanofi presently has a consensus rating of “Hold” and a consensus target price of $54.00.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Stock Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related stocks with our FREE daily email newsletter.